# Update on Rational Symptom-Based Treatment of

#### Gastroparesis/Gastropathy

Oley Foundation Symposium on "Managing Gastroparesis Day!"

> June 23, 2021 Hiroshi Mashimo MD PhD







#### Main Take-Home Points

- Besides diabetes, poor glucose control, medications, abdominal surgeries, pregnancy, etc. may lead to disorder of gastric emptying (too slow or too fast), stomach discomfort, nausea/vomit, bloating
- Measures of gastric emptying (timing/severity) poorly correlate with symptoms and overlaps with functional dyspepsia
- Mainstay of medical therapy is symptom-based:
   Promotilides
   Anti-nausea

  - · Pain reduction
  - Address coincident issues: bacterial overgrowth/dysbiosis, malnutrition/food aversion, neuroinflammation, anxiety/depression
- Non-medical treatments include:
- Herbs/acupuncture (Complementary Medicine)
   Electrical stimulators vs. pacers
   ? G-POEMs, Jejunostomy/venting G tube

#### Importance of Gastropathy in Diabetes Care


- Doctors generally screen for renal, ophthalmic, podiatry, cardiac and neurological problems in diabetic patients, but gastrointestinal (GI) problems are commonly under-recognized because patients do not volunteer information or are not directly asked by
- · Symptoms that can be confused with reflux disease, ulcers, gallstone, pancreas, irritable bowel, etc.
- · Can manifest by poor oral glycemic control
- Review medications: anticholinergics, antihistamines, antidepressants, narcotics; diabetes medicines such as amylin analogs and GLP-1 may worsen
- 19-76% patients in a diabetes clinic reported significant GI symptoms, most commonly:
  - · Early satiety
  - Reflux (e.g., heartburn)
     Abdominal pain
     Nausea/vomiting
     Diarrhea

  - Constipation

Zhao, X., Mashimo, H. Curr. Treatment Options in Gastroenterol. 2015; 13(4):452-472.

stomach paralysis Gastroparesis: Definition

delayed gastric emptying in the absence of a fixed mechanical obstruction of the pylorus or duodenum



Gastropathy in Diabetics:

potential other causes besides autonomic neuropathy


- Metabolic and endocrine: DKA, pregnancy, hypothyroidism, electrolyte imbalance, renal failure, neoplastic (breast/small cell/pancreas)
- **Medications**: anticholinergics, narcotics, β-adrenergics, Ca²+-channel blockers, glucagon, levodopa, loperamide, THC, alcohol, tobacco, etc.
- · Postsurgery: vagal nerve injury, partial gastrectomy, fundoplication, Whipple
- Infectious: acute viral gastroenteritis, EBV, varicella, parvovirus-like, Chagas, C. botulinum
- Gastritis: atrophic, pernicious anemia
   Rheumatologic: scleroderma, SLE, polymyositis/dermatomyositis
- Pseudo-obstruction: idiopathic, secondary (amyloidosis, MD, paraneoplastic)
   Electrical dysrhythmia: tachy, brady, or gastroduodenal dysynchrony
- Central nervous system: tumor, bulbar poliomyelitis, depression, CVA, head trauma, labyrinthine disorders, seizures, abdominal migraine
- Peripheral nervous system: Parkinson's, Guillain-Barre, MS, dysautonomia


# Important Emerging Key Concepts


- Stomach is not a simple bag


  - Different areas have different function
     Solid food emptied differently from liquids
- Relation of muscle and nerves to allow coordinated emptying
- Inflammation and altered sensory


understanding important for rational treatments
























Selective decrease in inhibitory pathway in major gastrointestinal motility disorders:

Examples:
Diabetic gastropathy
Achalasia
Pyloric stenosis
Pseudo-obstruction
Chronic constipation
Hirschsprungs Disease



suggestive symptoms and potential pathogenesis

- Early satiety/anorexia/food avoidance
- Bloating/postprandial fullness
- Heartburn
- Epigastric pain
- Nausea
- · Postprandial vomiting
- Weight loss

Defective accommodation reflex

Visceral hyper-sensitivity (sensory neuropathy)

Delayed emptying

# Etiological Implications (Ddx)

Timing minutes after meals hours after meals before breakfast

idiopathic, obstruction esophageal obstruction, diverticulum patent gastric outlet gastroparesis with stasis, intestinal obstruction, fistula cancer, inflammation

pregnancy brain tumor

History

History can suggest gastroparesis, but has limited usefulness in establishing etiology

# **EVALUATION**

Gastroparesis: Definition Scintigraphy delayed gastric emptying in the absence of a fixed mechanical obstruction of the pylorus or duodenum. Endoscopy/UGI-SBFT

#### **EVALUATING GASTRIC DYSMOTILITY**

- REVIEW MEDICATIONS!
- Endoscopy/UGI-SBFT
   rule out mucosal disease and obstruction
- Gastric Emptying Tests
- Gastro-duodenal Manometry
- Electrogastrography
- Barostat
- · PP for vagal integrity
- Smart Pill

# Gastric Emptying Tests: Indications


- To evaluate:


   Unexplained nausea/vomiting

   "Motility-like" non-ulcer dyspepsia (bloat, early satiety, anorexia)
- Severe gastroesopheal reflux disease refractory to medications

- medications
  Suspected gastroparesis in diabetics
  Suspected dumping/stasis after gastric surgery
  Suspected chronic intestinal pseudo-obstruction
  Possible re-evaluation in known gastroparetic in clinical trials of promotility agents

Not necessary if overt retention of food (on xray or endoscopy) after reliable fast





# Other Gastric Emptying Tests

- Gastric Emptying Breath Tests (GEBT, Advanced Breath Test Diagnostics) C<sup>ES</sup>-Spirulina Breath Test FDA-approved
- Intubation/aspiration
- Intubation/aspiration

  Ext. 750ml saline via ngt, check resid. after 30 min; nl <375ml

  variable aspiration, and checks only liquid emptying

  Radiological detection of radiopaque markers taken with meal (pointars, et al. 1997) or barium beefsteak meal


  Breath tests. 13C-octanoic acid


  indirect measure, noninvasive, reproducible, no radiation (stable isotope), less need normal intestinal absorption, liver metabolism, and lung function require validation against scintigraphy


  Acetaminophen absorption


  noninvasive measure of liquid emotying


- noninvasive measure of liquid emptying
   not extensively validated, need multiple blood samples, limited accuracy
- Single-photon-emission CT (SPECT) imaging of gastric accommodation
- SmartPill












# EGG interpretation

- Evaluation of frequency and power
- may define abnormality in a different subset of patients than those with emptying or manometry
- positive predictive value of abnormal EGG is estimated at 60%–90%
- suggested that dysrhythmias may be better indicators of symptoms such as nausea and early satiety than gastric emptying, and may better correlate with symptomatic responses to medications



**TREATMENT** 

# Current Treatment of Gastroparesis

- Correct underlying condition
   Review medications! control hyperglycemia!!! <- ? tid FS check
   ?insulin pump therapy in diabetics
- · Hydration and nutrition, check dentition
- Dietary changes
   small frequent meals, low residue, low fat
- Psychological measures: empathy/education, support groups, relaxation/hypnosis
- Medical treatments
- · Botulinum toxin?
- For failures, decompression (PEG-J) and nutrition (PEJ) only after trial of NG and NJ tubes
- Surgery g-POEMs? rare except outlet obstruction from PUD or carcinoma generally disappointing
   Gastric Electrical Stimulation/Pacing

#### Medications that Slow Gastric Emptying

- anticholinergic agents
- antidepressants
- beta-adrenergic agonists
- · calcium channel blockers
- · ganglion blocking agents
- levodopa
- nicotine
- · octreotide
- opiates tranquilizers
- vincristine

# Diabetes drugs that cause or worsen gastroparesis:

- amylin analog pramlintide (Symlin) both Type 1 and 2
   Vella A. et al Neurogastro and Motil 2002 14:123.
- GLP-1 agonist

  - Short acting: exanetide (Byetta), lixisenatide (Adlyxin), semaglutide (Rybelsus)
     Long acting: exanetide (Bydureon), liraglutide (Victoza), dulaglutide (Trulicity), semaglutide (Ozempic)
- May need to switch to DPP IV inhibitors: vildagliptin (Galvus), sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Trajenta)

For example, in clinical trials:

- •Nausea was 39% for exanetide vs. 5% for sitagliptin
- •Vomit was 19% for exanetide vs. 5% for sitagliptin

Berg et al. Diabetes Obes Metab 2011 13:982

# Three-step Dietary Treatment

STEP 1: rehydration Day 1-2

-sip Gatorade or salty bouillon solution to ingest goal 1-1.5L over 24 hours, multiple vitamin

-avoid citrus or highly sweetened drinks

STEP 2: diet advance to soups

-soups with noodles/rice and crackers, 6 small-volume meals per day, goal 1500 cal/day and maintain/gain weight -avoid fatty foods

STEP 3: introduction of more solid foods

-starches (require less electrocontractile work), white meat -avoid red meat, fresh vegetables, fiber

#### Pharmacological Treatment

- prokinetics
- antiemetics
- · pain control
- antibiotics (bacterial overgrowth)
- NOT octreotide (actually decreases postprandial antral motility index); however phase III augmentation of small bowel
- NOT muscarinic agonists alone (actually just discoordinated contractions)
   Sumatriptan, buspirone, sildenafil relax fundus for dyspepsia but may delay gastric emptying (Edmunds, M.C. et al., 1998 Alin. Pharmacol. & Therap. 12:167)

Medication	Other Mechanisms	Dosing	Comments
Dopamine D2-R anta	gonists		
*Metoclopramide (Reglan) Domperidone Itopride (Ganaton)	5-HT4 facilitate ACh release 5-HT3 antagonist peripheral D2R antagonist similar to domperidone also Ache inhibitor	5-20 mg po qid iv/liq/pr/nasal 10-30 mg qid 50mg	short course (4-12 wks) per FDA warning 10% CNS SEs; 1% dystonia not cross BBB; FDA IND w IRB no known cardiac SEs available in Asia
Motilin receptor ago	nists		
Erythromycin	stim cholin nerves  ↑ antral contrac	50-250 mg qid	strongest prokin iv; lower dose decr SEs 2x sudden death, tachyphylaxis w/in day
Azithromycin?			
5-HT4-R agonists			
Cisapride (Propulsid)	↑ ACh rel from ENS ↑ sm mus contractions 5HT3 antag, 5HT4 agonist	10-20mg qid	withdrawn 2000 compassionate use
Tegaserod	partial agonist	6 or 12 mg tid	
(Zelnorm)			
Prucalopride	highly selective agonist	2mg qD	avoids cardiac toxicity
Muscarinic receptor	agonist/Cholinesterase inhibi	tors	
Bethanechol	contractions not coordinated	25mg qid w/ prokin	sig AEs
	* The only medical	ation presently FDA-ing	dicated for gastroparesis; all others off-label

#### **Antiemmetics** Dopamine D2-R antag with prokinetic prochlorperzine (Compazine), trimethobenzamide (Tigan), thiethylperazine (Torecan) without prokinetic Serotonin 5-HT3-R antag ondansetron (Zofran), granisetron (Kytril) dolasetron (Anzemet), tropisetron (Navoban) desipramine, nortriptyline, amitriptyline Muscarinic M1-R antag scopolamine, hyoscyamine, clinidium (Quarzan) dimenhydrinate (Dramamine), meclizine (Antivert), promethazine (Phenergan) Histamine H1-R antag tetrahydrocannabinol, CBD/CBG etc. Cannabinoids Renzodiazenines lorazepam (Ativan) aprepitant (Emend) clonidine (Catapres) <-0.1mg patch, be careful with BP drop

#### Pain Control

- Pain from autonomic neuropathy? But more severe forms of diabetic neuropathy had LESS pain
- indomethacin and ketorolac may resolve slow wave abnormalities in DM and dyspeptic patients
- · caution ulcers and renal fct in DM TCAs at low doses
- SSRIs:
- paroxetine accelerate small intestinal transit
   duloxetine combined SS/NA RI
- NaSSA mirtazapine (Remeron)
- other drugs for neuropathic pain: gabapentin, topiramate, clonidine but uncertain role in gastroparesis
- avoid narcotics
   tramadol less μ-R action
- tramador Iess pura dutori
   methadone or transderm fentanyl less constipation
   alvimopan but not reverse effects of codeine on stomach
   methyl nalaxone (s.c.)

#### Upcoming/Newer Drugs Potential for Gastropathy

- Other 5HT agents: alosetron (re-approved for IBS-d), ARYx (ATI-7505), renzapride, mosapride, TD-5108(velusetrag)/2749
- Dopaminergic: TAK906

- CCKA antagonist: doxiglumide, loxiglumide

  · increase gastric and colonic motility, reduce visceral perception

  · Motilin receptor agonist: mitemenical (GM 611-05), ABT229

  · no antibacterial properties, acid resistant
- no antibacterial properties, acid resistant
   Opioid receptor modifiers: methylmaltrexone
- Neurotrophin-3 (BDNF)
- Guanyl cyclase agonist: linaclotide
- Ghrelin: Relamorelin, TZP101, pentapeptide
- Neurokinin/tachykinin analogues
- amylin antagonists


#### Potential Non-Drug Treatments


- Ginger weak 5HT<sub>3</sub>R antagonist
- Acupuncture point P6 (Neiguan point) reduction of nausea (Koch, K.L. et al. 1997)
   first trimester pregnancy (Evans, A.T., et al. 1993)

  - postoperative nausea and vomiting (Dundee, J.W., et al., 1989)
     cancer chemotherapy (Dundee, J.W., et al., 1991)
- Reliefband (Woodside Biomedicals, CA)
- Gastric electrical pacing (McCallum, R.W. et al., 1998)
- freq 10% above baseline, pulse width 300ms for entrainment
- Gastric electrical stimulation (GEMS Study Group, 1999)
   Enterra therapy (Medtronic)
- Gene therapy?

# **Refractory Patients**

- Switching prokinetic and antiemetic agents
- 2. Combining prokinetic agents
- 3. Gastrostomy/jejunostomy tubes
- Injecting botulinum toxin into the pylorus matter of patient selection, and presently not advocated unless part of clinical trial
- 5. Gastric-POEM?
- Implanting a gastric electric stimulator?





#### **SUMMARY**

- Gastropathy commonly under-recognized
   need to ask patients
   suspect in patients with nausea/vomit, dyspepsia, early satiety, poor appetite, poor glycemic control
- Diagnose by scintingraphy, rule out mucosal disease/obstruction by endoscopy and barium small bowel follow-through
- Review culprit medications: anticholinergics, antihistamines, narcotics; amylin analogs and GLP-1 may exacerbate
- Correct underlying metabolic disorders, initiate three-step dietary progression
- $\bullet$  Treatment: prokinetics, antiemetics, and pain control

